Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial-Reference-Cited by-同舟云学术

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

Published:2006-09 Issue:9 Volume:7 Page:719-727
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Douillard Jean-Yves,Rosell Rafael,De Lena Mario,Carpagnano Francesco,Ramlau Rodryg,Gonzáles-Larriba Jose Luis,Grodzki Tomasz,Pereira Jose Rodrigues,Le Groumellec Alain,Lorusso Vito,Clary Claude,Torres Antonio J,Dahabreh Jabrail,Souquet Pierre-Jean,Astudillo Julio,Fournel Pierre,Artal-Cortes Angel,Jassem Jacek,Koubkova Leona,His Patricia,Riggi Marcello,Hurteloup Patrick

Publisher

Elsevier BV

Subject

Oncology

Reference17 articles.

1. Estimating the world cancer burden: Globoscan 2000;Parkin;Int J Cancer,2001

2. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report;Fry;Cancer,1999

3. Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances;Strauss;Hematol Oncol Clin N Am,2005

4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials;BMJ,1995

5. Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer;Johnson;Clin Cancer Res,2005

Cited by 1392 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer;Cancer Treatment Reviews;2024-09

2. The Role of Adjuvant Chemotherapy in pN1 (IIB/IIIA) NSCLC Patients Who Undergo Pneumonectomy: Is It Still Justified in the Modern Era?;Cancers;2024-08-31

3. Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario;Current Oncology;2024-08-30

4. Updated review of perioperative treatment for non-small-cell lung cancer in the new era of immune checkpoint inhibitors: past, present, and future;Japanese Journal of Clinical Oncology;2024-08-20

5. Peripheral CD8+PD-1+ T cells as novel biomarker for neoadjuvant chemoimmunotherapy in humanized mice of non-small cell lung cancer;Cancer Letters;2024-08